Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
Gilead Sciences
Colleen F Kelley; Maribel Acevedo-Quiñones; Allison L Agwu; Anchalee Avihingsanon; Paul Benson; Jill Blumenthal; Cynthia Brinson; Carlos Brites; Pedro Cahn; Valeria D Cantos; Jesse Clark; Meredith Clement; Cathy Creticos; Gordon Crofoot; Ricardo S Diaz; Susanne Doblecki-Lewis; Jorge A Gallardo-Cartagena; Aditya Gaur; Beatriz Grinsztejn; Shawn Hassler; Juan Carlos Hinojosa; Theo Hodge; Richard Kaplan; Marcus Lacerda; Anthony LaMarca; Marcelo H Losso; José Valdez Madruga; Kenneth H Mayer; Anthony Mills; Karam Mounzer; Nkosiphile Ndlovu; Richard M Novak; Alma Perez Rios; Nittaya Phanuphak; Moti Ramgopal; Peter J Ruane; Jorge Sánchez; Breno Santos; Patric Schine; Tanya Schreibman; LaShonda Y Spencer; Olivia T Van Gerwen; Ricardo Vasconcelos; Jose Gabriel Vasquez; Zwelethu Zwane; Stephanie Cox; Chris Deaton; Ramin Ebrahimi; Pamela Wong; Renu Singh; Lillian B Brown; Christoph C Carter; Moupali Das; Jared M Baeten; Onyema Ogbuagu; PURPOSE 2 Study Team